AIS |
Adenocarcinoma in situ |
ALTS |
ASCUS/LSIL Triage Study |
AGC |
Atypical galndular cells |
ASC |
Atypical squamous cells |
ASC |
American Society of Cytology |
ASCP |
American Society of Clinical Pathologists |
ASC-H |
Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion |
ASC-US |
Atypical squamous cells of undetermined significance |
CAP |
College of American Pathologists |
CIS |
Carcinoma in situ |
CIN |
Cervical intraepithelial neoplasia |
CP |
Conventional preparation |
DES |
Diethylstilbestrol |
HSIL |
High-grade squamous intraepitheial lesion |
FIGO |
International Federation of Gynecology and Obstetrics |
HPV |
Human Papilloma Virus |
IARC |
International Agency for Research on Cancer |
ISH |
In situ Hybridization |
IUD |
Intrauterine device |
LBP |
Liquid-based preparation |
LEEP |
Loop electrosurgical |
LMP |
Last menstrual period (in days) |
LUS |
Lower uterine segment |
LSIL |
Low-grade squamous intraepithelial lesion |
N/C |
Nuclear/cytoplasmic ratio |
NCI |
National Cancer Institute (Bethesda USA) |
NILM |
Negative for intraepithelial lesion or malignancy |
NOS |
Not otherwise specified |
PCR |
Polymerase Chain Reaction |
RB |
RetinoBlastoma (gene) |
RCH |
Reserve cell hyperplasia |
SCUC |
Small cell undifferentiated carcinoma |
SCC |
Squamous cell carcinoma |
SIL |
Squamous intraepithelial lesion |
TBS |
The Bethesda System |
TCC |
Transitional cell carcinoma (urothelial) |
TNM |
Tumour Node Metastasis |
T zone |
Transformation zone |
UICC |
International Union Against Cancer |
WHO |
World Health Organization |